Farallon discloses 6.1% Centessa (NASDAQ: CNTA) ownership stake

Rhea-AI Filing Summary

Farallon Capital Management and related individuals report beneficial ownership of 9,370,093 Centessa Pharmaceuticals ordinary shares, equal to 6.1% of the class based on 154,731,309 shares outstanding as of June 10, 2026. The stake, held through several Farallon investment partnerships via American Depositary Shares, reflects an approximate aggregate investment cost of $325,995,909. The group describes Centessa as an attractive investment and may buy more shares, sell, hedge, or take other actions over time to maximize the value of its position, while stating it has no specific corporate-change plans beyond what is outlined in the filing.

Insights

Event-driven equity analyst

Farallon reveals a sizeable, flexible 6.1% position in Centessa.

Farallon Capital Management and affiliated individuals collectively beneficially own 9,370,093 Centessa ordinary shares, or 6.1% of outstanding, with an approximate net investment cost of $325,995,909. The shares are held across multiple Farallon funds via American Depositary Shares.

The group characterizes Centessa as an attractive investment and outlines a wide range of potential future actions, including additional purchases, sales, hedging, and other steps to maximize investment value. No specific plans for corporate changes are detailed, but the use of a Schedule 13D and the broad language can signal an active, research-intensive stance.

Future disclosures, including the detailed sixty-day trading history referenced in Exhibit 99.2 and any subsequent ownership updates, will further clarify how Farallon adjusts its stake around key company or market developments.

Key Figures

Beneficially owned shares: 9,370,093 shares Ownership percentage: 6.1% of class Shares outstanding: 154,731,309 shares +4 more

7 metrics

Beneficially owned shares 9,370,093 shares Ordinary Shares represented by ADSs beneficially owned by reporting persons

Ownership percentage 6.1% of class Based on 154,731,309 ordinary shares outstanding as of June 10, 2026

Shares outstanding 154,731,309 shares Ordinary shares outstanding as of June 10, 2026 per issuer Form 8-K

Net investment cost $325,995,909 Approximate net investment cost for Ordinary Shares represented by ADSs held by Farallon Funds

Event date June 16, 2026 Date of event requiring filing of this Schedule 13D

ADS ratio 1 ADS = 1 ordinary share Each American Depositary Share represents one Ordinary Share

Number of Farallon funds 9 funds FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI, FHPM

Key Terms

beneficially owned, American Depositary Shares, investment manager, open-market transactions, +1 more

5 terms

beneficially owned financial

"The Ordinary Shares, represented by ADSs, reported hereby as beneficially owned by the Reporting Persons are held directly by the following investment partnerships"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

American Depositary Shares financial

"The CUSIP number 152309100 has been assigned to the American Depositary Shares ("ADSs") of the Issuer"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

investment manager financial

"Farallon Capital Management, L.L.C., a Delaware limited liability company (the "Investment Manager"), which is the investment manager of certain investment partnerships"

open-market transactions financial

"All of such transactions were open-market transactions."

Open-market transactions are purchases or sales of a company’s securities that take place on public exchanges rather than through private agreements. They matter to investors because these trades change the number of shares available, can move the stock price, and often signal management’s view of the company’s value—like a store restocking or clearing shelves, altering supply and the price shoppers see.

Rule 13d-1(k) regulatory

"There is filed herewith as Exhibit 99.1 a written agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/24/2026 - 06:32 PM Accepted by SEC EDGAR 06/24/2026 - 06:32 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Centessa Pharmaceuticals plc

(Name of Issuer)

Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares")

(Title of Class of Securities)

152309100

(CUSIP Number)

Hannah E. Dunn
Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100
San Francisco, CA, 94111
(415) 421-2132

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/16/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

FARALLON CAPITAL MANAGEMENT, L.L.C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Dapice Joshua J.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Dreyfuss, Philip D.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Dunn Hannah E.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Gehani, Varun N.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Giauque, Nicolas

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Husen, Avner A.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Kim, David T.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Linn, Michael G.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Luo Patrick (Cheng)

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Roberts, Jr., Thomas G.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Saito Edric C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Short Daniel S.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Spokes, Andrew J. M.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Warren, John R.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 152309100

1

Name of reporting person

Wehrly, Mark C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,370,093.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,370,093.00

11

Aggregate amount beneficially owned by each reporting person

9,370,093.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares")
(b)	Name of Issuer: Centessa Pharmaceuticals plc
(c)	Address of Issuer's Principal Executive Offices: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, UNITED KINGDOM , WA14 2DT.
Item 2.	Identity and Background
(a)	This Schedule 13D is filed by the entity and persons listed below, all of whom together are referred to herein as the "Reporting Persons." (i) Farallon Capital Management, L.L.C., a Delaware limited liability company (the "Investment Manager"), which is the investment manager of certain investment partnerships, including the Farallon Funds (as defined in Item 5), with respect to the Ordinary Shares, represented by ADSs (as defined below), held by the Farallon Funds; and (ii) The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Investment Manager, with respect to the Ordinary Shares, represented by ADSs, held by the Farallon Funds: Joshua J. Dapice ("Dapice"); Philip D. Dreyfuss ("Dreyfuss"); Hannah E. Dunn ("Dunn"); Varun N. Gehani ("Gehani"); Nicolas Giauque ("Giauque"); Avner A. Husen ("Husen"); David T. Kim ("Kim"); Michael G. Linn ("Linn"); Patrick (Cheng) Luo ("Luo"); Thomas G. Roberts, Jr. ("Roberts"); Edric C. Saito ("Saito"); Daniel S. Short ("Short"); Andrew J. M. Spokes ("Spokes"); John R. Warren ("Warren"); and Mark C. Wehrly ("Wehrly"). Dapice, Dreyfuss, Dunn, Gehani, Giauque, Husen, Kim, Linn, Luo, Roberts, Saito, Short, Spokes, Warren and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons." There is no CUSIP assigned to the Ordinary Shares. The CUSIP number 152309100 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol "CNTA." Each ADS represents one Ordinary Share.
(b)	The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.
(c)	The principal business of the Investment Manager is to act as the investment manager of various investment vehicles and partnerships, including the Farallon Funds. The principal occupation of Giauque is serving as Senior Managing Member of each of the Investment Manager and Farallon Partners, L.L.C., which is the general partner of certain investment partnerships advised by the Investment Manager, and as the Senior Manager of certain other general partners of investment partnerships advised by the Investment Manager. The principal occupation of each other Farallon Individual Reporting Person is serving as a Managing Member of each of the Investment Manager and Farallon Partners, L.L.C., and as a Manager of certain other general partners of investment partnerships advised by the Investment Manager.
(d)	None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	The jurisdiction of organization of the Investment Manager is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque, Luo and Spokes, is a citizen of the United States. Giauque is a citizen of France. Luo is a citizen of China. Spokes is a citizen of the United Kingdom.
Item 3.	Source and Amount of Funds or Other Consideration
	The approximate net investment cost for the Ordinary Shares, represented by ADSs, held by the Farallon Funds is $325,995,909.
Item 4.	Purpose of Transaction
	The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4. The Reporting Persons believe the securities of the Issuer represent an attractive investment opportunity. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending upon various factors, including, without limitation, the Issuer's financial position and strategic direction, overall market conditions, general economic and industry conditions, other investment opportunities available to the Reporting Persons, the liquidity requirements of the Reporting Persons, price levels of the Ordinary Shares and the ADSs, and any contractual provisions to which the Reporting Persons may then be subject, the Reporting Persons in the future may take actions with respect to their investment position in the Issuer as they deem appropriate, including, without limitation, purchasing additional Ordinary Shares or ADSs, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; selling, exchanging, converting, pledging or financing some or all of the securities reported herein, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; engaging in hedging or similar transactions with respect to Ordinary Shares or ADSs, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; and taking any other action to maximize the value of the Reporting Persons' investment position in the Issuer. Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The information set forth in Rows 7 through 13 of the cover page hereto for each Reporting Person is incorporated herein by reference for each such Reporting Person. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 154,731,309 Ordinary Shares outstanding as of June 10, 2026, as reported by the Issuer in its Form 8-K filed with the Securities and Exchange Commission on June 12, 2026. The Ordinary Shares, represented by ADSs, reported hereby as beneficially owned by the Reporting Persons are held directly by the following investment partnerships, of which the Investment Manager is the investment manager: (i) Farallon Capital Partners, L.P., a California limited partnership ("FCP"); (ii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"); (iii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"); (iv) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"); (v) Four Crossings Institutional Partners V, L.P., a Delaware limited partnership ("FCIP V"); (vi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"); (vii) Farallon Capital (AM) Investors, L.P., a Delaware limited partnership ("FCAMI"); (viii) Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership ("F5MI"); and (ix) Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership ("FHPM"). FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the "Farallon Funds."
(b)	The information set forth in Rows 7 through 13 of the cover page hereto for each Reporting Person is incorporated herein by reference for each such Reporting Person.
(c)	The dates, number of ADSs involved and the price per ADS (excluding commissions) for all transactions in the ADSs by the Farallon Funds in the past sixty days are set forth in Exhibit 99.2 attached hereto and such information is incorporated herein by reference. All of such transactions were open-market transactions.
(d)	No person (other than the Reporting Persons, the Farallon Funds, and the general partner of each Farallon Fund) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The disclosure set forth in Items 4 and 5 above is hereby incorporated by reference in this Item 6. Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any securities of the Issuer, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.
Item 7.	Material to be Filed as Exhibits.
	There is filed herewith as Exhibit 99.1 a written agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. There is filed herewith as Exhibit 99.2 the sixty-day trading history referenced in Item 5(c).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FARALLON CAPITAL MANAGEMENT, L.L.C.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, Managing Member
Date:	06/24/2026

Dapice Joshua J.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Dreyfuss, Philip D.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Dunn Hannah E.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn
Date:	06/24/2026

Gehani, Varun N.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Giauque, Nicolas

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Husen, Avner A.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Kim, David T.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Linn, Michael G.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Luo Patrick (Cheng)

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Roberts, Jr., Thomas G.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Saito Edric C.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Short Daniel S.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Spokes, Andrew J. M.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Warren, John R.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

Wehrly, Mark C.

Signature:	/s/ Hannah E. Dunn
Name/Title:	Hannah E. Dunn, as attorney-in-fact
Date:	06/24/2026

FAQ

How big is Farallon’s stake in Centessa Pharmaceuticals (CNTA)?

Farallon and related reporting persons beneficially own 9,370,093 Centessa ordinary shares, representing 6.1% of the class. This percentage is based on 154,731,309 ordinary shares outstanding as of June 10, 2026, as reported by the company.

What did Farallon pay for its Centessa (CNTA) position?

The filing states Farallon funds’ approximate net investment cost is $325,995,909 for the Centessa ordinary shares held via ADSs. This figure reflects cumulative investment, not current market value, and helps investors gauge the scale of Farallon’s financial commitment.

How does Farallon hold its Centessa (CNTA) shares?

Farallon’s Centessa position is held through several investment partnerships, collectively called the Farallon Funds. They own American Depositary Shares, each representing one Centessa ordinary share, with CUSIP 152309100 for the ADSs quoted on Nasdaq under symbol CNTA.

What are Farallon’s intentions regarding its Centessa (CNTA) investment?

Farallon describes Centessa as an attractive investment opportunity and plans to review the position on an ongoing basis. Depending on conditions, it may buy more shares, sell, hedge, or take other steps it believes will maximize the value of its investment.

Does Farallon have specific plans to change control at Centessa (CNTA)?

The reporting persons state they currently have no specific plans or proposals involving actions listed in Item 4(a)-(j), such as mergers or control changes. However, they reserve the right to reconsider and potentially pursue such actions in the future.

Were Farallon’s recent Centessa (CNTA) trades open-market transactions?

Yes. The filing notes that all transactions in Centessa ADSs by the Farallon Funds during the past sixty days were open-market transactions. Detailed dates, share amounts, and prices are provided in Exhibit 99.2 referenced in the document.